Journal Article Preprint Epublish 1 citation
PubMed: 40093054 DOI: 10.1101/2025.03.06.641285
A patient-derived ovarian cancer organoid platform to study susceptibility to natural killer cells.
bioRxiv
Authors: Marisa Mercadante, Armin Scheben, Jacob Estrada, Jan Savas-Carstens, William Sullivan, Nicholas Housel, Tatiana Volpari, Jax Hebner, Maria Sapar, Tom Rusielewicz, Frederick J Monsma, Stefan Semrau, Yinan Wang, Laura A Martin
Affiliations
- The New York Stem Cell Foundation Research Institute, New York, NY.
- The Stevens Institute of Technology, Hoboken, NJ.
Abstract
Intratumoral heterogeneity drives therapy resistance and relapses in advanced stage cancers, such as ovarian cancer. Here, we present a live cell imaging assay using patient-derived ovarian cancer organoids for real time capture and quantification of natural killer cell-mediated apoptotic events in >500 organoids simultaneously. Our assay revealed significant inter- and intratumor response heterogeneity and identified a rare resistant organoid population, opening avenues to test immunomodulatory strategies that overcome resistance.
MeSH
Cells, Killer Cells, Natural, Neoplasms, Organoids, Ovarian Neoplasms